ImmunoGen up on positive data from rare blood cancer drug trial

ImmunoGen

09/06/2023 17:22

** Shares of drugmaker ImmunoGen Inc  IMGN.O  rise 7.4% to
$16.92 
    ** Says patients with a rare blood cancer called blastic
plasmacytoid dendritic cell neoplasm showed response after
treatment with co's experimental drug pivekimab sunirine,
according to updated data from a mid-stage trial 
    ** Adds no new safety signals were observed and the drug
continues to show "manageable safety"
    ** IMGN shares are now up more than three times since early
May, when co reported positive data from its ovarian cancer
drug's late-stage trial 
    ** Including session's move, ImmunoGen has now gained ~$2.6
bln in market cap since early May, according to no. of shares
outstanding in the latest quarterly filing

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))